AbbVie (NYSE:ABBV) Updates FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 13.910-14.110 for the period, compared to the consensus earnings per share estimate of 14.250. The company issued revenue guidance of -. AbbVie also updated its Q2 2026 guidance to 3.570-3.610 EPS.

AbbVie Trading Up 1.1%

Shares of ABBV stock traded up $2.83 during mid-day trading on Tuesday, reaching $257.58. The stock had a trading volume of 834,944 shares, compared to its average volume of 7,170,011. The stock’s 50-day moving average price is $221.27 and its two-hundred day moving average price is $220.47. AbbVie has a 52-week low of $184.63 and a 52-week high of $261.64. The firm has a market capitalization of $455.10 billion, a PE ratio of 126.86, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the business posted $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities research analysts forecast that AbbVie will post 14.28 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is presently 340.89%.

Analysts Set New Price Targets

Several analysts have weighed in on the company. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Morgan Stanley raised their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Evercore set a $235.00 target price on AbbVie in a report on Friday, May 15th. Piper Sandler reissued an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Wells Fargo & Company set a $260.00 price objective on shares of AbbVie in a research report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $256.67.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a European Commission approval for TEPKINLY (epcoritamab) plus lenalidomide and rituximab to treat relapsed or refractory follicular lymphoma. The approval expands the drug’s reach in Europe and supports AbbVie’s oncology growth story. Article: AbbVie Announces TEPKINLY approval by the European Commission
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 and kept an overweight rating, signaling continued analyst confidence in the stock’s upside. Article: AbbVie price target raised by Cantor Fitzgerald
• Neutral Sentiment: AbbVie is also getting some investor focus ahead of its upcoming quarterly report, with analysts watching whether Skyrizi and Rinvoq can offset continued pressure from Humira declines. Article: Will Immunology Franchise Aid AbbVie’s Upcoming Q2 Results?
• Negative Sentiment: AbbVie cut its second-quarter 2026 EPS guidance to $3.57-$3.61, below the consensus estimate of $3.77, which could pressure shares. FY 2026 EPS guidance was also lowered to $13.91-$14.11 versus the Street’s $14.25 forecast.

Institutional Investors Weigh In On AbbVie

A number of large investors have recently made changes to their positions in ABBV. Brighton Jones LLC boosted its position in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC raised its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. lifted its stake in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after buying an additional 789 shares in the last quarter. Ieq Capital LLC boosted its holdings in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC boosted its holdings in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after buying an additional 612,702 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.